OncoMatch/Clinical Trials/NCT04278222
Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC)
Is NCT04278222 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Anlotinib Plus Toripalimab for gastric cancer.
Treatment: Anlotinib Plus Toripalimab — This study is designed to evaluate the efficacy and safety of the combination of Anlotinib wiht Toripalimab in advanced gastric cancer with ECOG 2 as first-line regimen.
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Biomarker criteria
Excluded: HER2 (ERBB2) positive
harboring HER2 positive including IHC 3+ or IHC 2+ with Fish positive
Excluded: MMR deficient
dMMR/MSI-H
Excluded: MSI high
dMMR/MSI-H
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 2–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: anlotinib
have received anlotinib
Cannot have received: immune checkpoint inhibitor
have received...other immune checkpoint inhibitor
Lab requirements
Blood counts
HB ≥ 90g/L, ANC ≥ 1.5 × 10^9/L, PLT ≥ 80 × 10^9/L
Kidney function
Serum Cr ≤ 1.5 × ULN
Liver function
BIL <1.5x ULN, ALT and AST <2.5x ULN; if liver metastases, BIL <3x ULN, ALT and AST <5x ULN
the main organ function to meet the following criteria: HB ≥ 90g / L, ANC ≥ 1.5 × 109 / L, PLT ≥ 80 × 109 / L,BIL <1.5 times the upper limit of normal (ULN), ALT and AST <2.5 × ULN and if liver metastases, BIL < 3 × ULN, ALT and AST <5 × ULN; Serum Cr ≤ 1.5 × ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify